Heavy Menstrual Bleeding (HMB) Epidemiology Forecast 2025-2034

According to the National Library of Medicine, around 10 out of 100 women experience heavy periods. Hormone therapy and painkillers are the common treatments for heavy menstrual bleeding. Other alternatives include non-hormonal medications, surgical interventions, and lifestyle management. This condition not only impacts the quality of life but can also lead to iron deficiency. In low- and middle-income countries, underdiagnosis or misdiagnosis of heavy menstrual bleeding often occurs due to inadequate healthcare infrastructure.

Heavy Menstrual Bleeding (HMB) Epidemiology Forecast Report Coverage

The “Heavy Menstrual Bleeding (HMB) Epidemiology Forecast Report 2034” offers comprehensive information on the prevalence and demographics of heavy menstrual bleeding (HMB). It projects the future incidence and prevalence rates of heavy menstrual bleeding (HMB) across various populations. The report highlights patterns in the prevalence of heavy menstrual bleeding (HMB) over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of Heavy Menstrual Bleeding (HMB) in the 8 major markets, namely, the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India.

Regions Covered

• The United States
• EU-4 (Germany, France, Italy, Spain) and the United Kingdom
• Japan
• India

Heavy Menstrual Bleeding (HMB): Disease Overview

Heavy menstrual bleeding, also known as menorrhagia, refers to heavy or prolonged vaginal bleeding during a menstrual cycle. It occurs when a woman bleeds for more than 7 days, or a change of sanitary pad is required every hour. Heavy menstrual bleeding can disrupt life and may indicate a more severe health problem. Hormone imbalances, the formation of uterine fibroids and polyps, and pregnancy complications, among others, are some of the common causes of heavy menstrual bleeding.

• As per the article published in the International Journal of Gynecology & Obstetrics 162 (2023), one-fourth of reproductive-age menstruators experience heavy menstrual bleeding as a symptom.
• According to the Centers for Disease Control and Prevention, 10 million or 1 in 5 American women are affected by heavy menstrual bleeding.
• Women’s Health Concern, the patient arm of the British Menopause Society, states that heavy menstrual bleeding is one of the common reasons for women to visit their general practitioner, with 1 out of 3 menstruating women describing their period as heavy.
• In low-income and middle-income countries (LMICs), heavy menstrual bleeding is highly prevalent and severely affects the quality of life of women, according to the article published in the Lancet Global Health (2023).

Heavy Menstrual Bleeding (HMB): Treatment Overview

The heavy menstrual bleeding (HMB) treatment focuses on reducing menstrual blood loss, addressing root causes, and improving the quality of life of the female patient. The therapeutic approach varies based on the severity of the condition, the woman's age, reproductive goals, and overall health. Hormonal therapies such as combined estrogen-progestin pills and progestins are the first-line treatment for managing heavy menstrual bleeding. Non-hormonal options such as ibuprofen and naproxen are also used to reduce menstrual bleeding and pain by inhibiting the production of prostaglandins.

Epidemiology

The Heavy Menstrual Bleeding (HMB) epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for heavy menstrual bleeding (HMB) by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for heavy menstrual bleeding (HMB) and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

Country-wise Heavy Menstrual Bleeding (HMB) Epidemiology

The heavy menstrual bleeding (HMB) epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

Several factors such as genetics, healthcare access, and socio-economic conditions, affect the prevalence rate of heavy menstrual bleeding in different regions. In countries where polycystic ovary syndrome (PCOS) or other hormonal disorders are prevalent, women are more likely to experience heavy menstrual bleeding as a symptom. In India, it is reported that 60% of the 355 million menstruating women may require medical help to deal with heavy periods at some point in their lives.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of heavy menstrual bleeding (HMB) based on several factors.
• Heavy Menstrual Bleeding (HMB) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India)
• The report helps to identify the patient population, the unmet needs of heavy menstrual bleeding (HMB) are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of heavy menstrual bleeding (HMB) epidemiology in 8MM?
• What will be the total number of patients with heavy menstrual bleeding (HMB) across the 8MM during the forecast period (2025-2034)?
• What was the country-wise prevalence of heavy menstrual bleeding (HMB) in the 8 major markets in the historical period?
• Which country will have the highest number of heavy menstrual bleeding (HMB) patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of heavy menstrual bleeding (HMB) during the forecast period of 2025-2034?
• What are the currently available treatments for heavy menstrual bleeding (HMB)?
• What are the disease risks, signs & symptoms, and unmet needs of heavy menstrual bleeding (HMB)?

This product will be delivered within 3-5 business days.